{"id":145956,"date":"2025-03-10T11:27:35","date_gmt":"2025-03-10T05:57:35","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=145956"},"modified":"2025-03-10T11:44:58","modified_gmt":"2025-03-10T06:14:58","slug":"pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/","title":{"rendered":"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S."},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1008979948\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1578867823\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Price action<\/strong><\/h2><p>With a market capitalization of Rs. 93,143.48 Crores on Monday, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/LUPIN\" target=\"_blank\" rel=\"noreferrer noopener\">Lupin Limited<\/a><\/strong> rose by upto 2.6 percent after making a high of Rs. 2081.95 compared to its previous closing price of Rs. 2028.90.<\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"296\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2025\/03\/Screenshot-2025-03-10-112933-1024x296.png\" alt=\"\" class=\"wp-image-145960\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2025\/03\/Screenshot-2025-03-10-112933-980x284.png 980w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2025\/03\/Screenshot-2025-03-10-112933-480x139.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened<\/strong><\/h2><p>Lupin Limited engaged<strong> <\/strong>in developing and marketing generic formulations, biotechnology products, and APIs globally,<strong> <\/strong>has launched Rivaroxaban Tablets USP, 2.5 mg, in the U.S. following FDA approval.&nbsp;<\/p><p>The tablets are bioequivalent to Janssen Pharmaceuticals&#8217; Xarelto 2.5 mg and are used to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and to lower the risk of major blood clot events in patients with peripheral artery disease (PAD), particularly those who have recently undergone lower extremity revascularization due to symptomatic PAD and the Rivaroxaban 2.5 mg had U.S. sales of approximately $446 million in 2025.<\/p><div class=\"trade-content_5\" id=\"trade-1179021758\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Lupin at Glance<\/strong><\/h2><p>The company specializes in generics, biotechnology, and APIs it focuses on providing high-quality, affordable medicines across various therapeutic areas, including cardiovascular, oncology, and respiratory.&nbsp;<\/p><p>Lupin is a global pharmaceutical leader with a presence in over 100 countries. It ranks 12th globally in generics by sales and is the largest generic company in the US, Australia, South Africa, and more.&nbsp;<\/p><p>With annual sales of $2.4 billion and 23,000+ employees, Lupin focuses on sustainable growth and innovation, operating 15 manufacturing sites and 7 R&amp;D sites globally, and has planned to set up 58MW Renewable energy capacity by FY25.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Key Business&nbsp; Developments (Q3FY25)<\/strong><\/h2><p>The company has acquired Eli Lilly\u2019s Huminsulin to enhance India&#8217;s Diabetes Portfolio, and they have partnered to commercialize NaMuscla in Argentina &amp; Colombia, and have filed&nbsp; Ranibizumab for European Union (EU) markets.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also Read:<\/strong><\/p><\/blockquote><figure class=\"wp-block-embed is-type-wp-embed is-provider-trade-brains wp-block-embed-trade-brains\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"XJxlFE2Ksn\"><a href=\"https:\/\/tradebrains.in\/features\/psu-stock-jumps-4-after-receiving-multiple-orders-worth-76-cr-from-indian-railways\/\">PSU stock jumps 4% after receiving multiple orders worth \u20b976 Cr from Indian Railways<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; visibility: hidden;\" title=\"&#8220;PSU stock jumps 4% after receiving multiple orders worth \u20b976 Cr from Indian Railways&#8221; &#8212; Trade Brains\" src=\"https:\/\/tradebrains.in\/features\/psu-stock-jumps-4-after-receiving-multiple-orders-worth-76-cr-from-indian-railways\/embed\/#?secret=2pJGmlb5fX#?secret=XJxlFE2Ksn\" data-secret=\"XJxlFE2Ksn\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financials&nbsp;<\/strong><\/h2><p>The company&#8217;s revenue rose by 11.38 percent from Rs. 5,226.78 crore to Rs. 5,821.42 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 613.12 crores to Rs. 855.16 crore during the same period.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Sridhar J&nbsp;<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"trade-content-10\" id=\"trade-3533984447\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-3903746842\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval. Price action With a market capitalization of Rs. 93,143.48 Crores on Monday, the shares of Lupin Limited rose by upto 2.6 percent [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":125304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[],"class_list":["post-145956","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S. - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S.\" \/>\n<meta property=\"og:description\" content=\"The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T05:57:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T06:14:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/\",\"name\":\"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S. - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"datePublished\":\"2025-03-10T05:57:35+00:00\",\"dateModified\":\"2025-03-10T06:14:58+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S. - Trade Brains Features","description":"The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S.","og_description":"The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-03-10T05:57:35+00:00","article_modified_time":"2025-03-10T06:14:58+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/","name":"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S. - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","datePublished":"2025-03-10T05:57:35+00:00","dateModified":"2025-03-10T06:14:58+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The shares of the pharmaceutical company, specializing in developing and marketing generic formulations, biotechnology products, and APIs globally, jumped upto 3 percent upon launching a New Drug Application from the U.S. FDA approval.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-3-after-company-to-launch-rivaroxaban-tablets-in-u-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 3% after company to launch Rivaroxaban Tablets in U.S."}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=145956"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145956\/revisions"}],"predecessor-version":[{"id":145961,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145956\/revisions\/145961"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/125304"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=145956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=145956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=145956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}